1. Home
  2. CODA vs CGTX Comparison

CODA vs CGTX Comparison

Compare CODA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

HOLD

Current Price

$11.66

Market Cap

134.4M

Sector

Industrials

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

110.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CODA
CGTX
Founded
1994
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.4M
110.8M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
CODA
CGTX
Price
$11.66
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
126.8K
993.6K
Earning Date
06-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
15.62
62.79
EPS
0.08
N/A
Revenue
$20,316,161.00
N/A
Revenue This Year
$18.28
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
$148.19
N/A
Revenue Growth
4.98
N/A
52 Week Low
$5.98
$0.22
52 Week High
$18.00
$3.83

Technical Indicators

Market Signals
Indicator
CODA
CGTX
Relative Strength Index (RSI) 46.25 53.36
Support Level $10.81 $1.19
Resistance Level $12.22 $1.36
Average True Range (ATR) 0.51 0.09
MACD 0.05 -0.01
Stochastic Oscillator 51.68 30.43

Price Performance

Historical Comparison
CODA
CGTX

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: